TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, look at the top medical stories of the week. This week’s topics include when to clamp the …
Early Interventions for Autism; Imaging After Stenting Read More »
Wheat is an assistant professor of emergency medicine. Sarabu is a clinical assistant professor of pediatrics. Lokmic-Tomkins is an associate professor of nursing. Climate change is contributing to the inequitable suffering of billions of people around the world. Driven by human greenhouse gas emissions, climate-related hazards — including heat waves, floods, wildfires, and disease outbreaks …
We Need ICD Codes for Climate-Linked Health Outcomes Read More »
Adding immunotherapy to neoadjuvant chemotherapy for resectable gastroesophageal cancer led to higher rates of disease downstaging and pathologic complete response (pCR), an exploratory analysis of a randomized trial showed. Downstaging favored the addition of atezolizumab (Tecentriq) whether defined as no evidence of tumor in the primary lesion (ypT0), residual tumor less than 5 cm (ypT0-2), …
Chemoimmunotherapy Improves Pathologic Outcomes in Gastroesophageal Carcinoma Read More »
Upfront endoscopic necrosectomy may be suitable for certain patients with confirmed or suspected infected necrotizing pancreatitis, results of a small randomized trial suggested. In 70 patients undergoing drainage with endoscopic transluminal stenting, upfront necrosectomy immediately afterward led to fewer subsequent interventions to achieve treatment success compared with when this procedure was reserved for stubborn cases …
Two Approaches for Infected Necrotizing Pancreatitis Go Head-to-Head Read More »
Not intended for U.S. and UK Media Berlin, June 29, 2023 – Bayer today announced the two-year (96 weeks) topline results of the pivotal clinical trial PHOTON investigating its novel aflibercept 8 mg with extended dosing regimens of up to 24 weeks in diabetic macular edema (DME) compared to the current standard of care EyleaTM …
Not intended for U.S. and UK Media Berlin, June 22, 2023 – Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective …
New York, June 20, 2023 – Bayer today announced its Crop Science Division will capitalize on opportunities presented by the shift to regenerative agriculture to grow in adjacent markets in addition to its core business of seeds, traits, crop protection and digital. At its 2023 Innovation Summit, the company identified growth potential in segments like …
Berlin, May 16, 2023 – Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian’s first U.S. FDA Fast Track Designation for the …
Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso New Pharmaceuticals products deliver strong growth – headwinds in Chinao Consumer Health continues to grow EBITDA before special items: 4.471 billion euros (minus 14.9 percent)o Glyphosate and inflation weigh on earningso …
Durham, N.C., Monheim, Germany, August 29, 2023 – Pairwise, a food and agriculture company known for bringing the first gene-edited food to the U.S. market, and Bayer today announced a new five-year, multi-million Dollar agreement focused on innovations in short-stature corn. This new program leverages Pairwise’s Fulcrum™ platform and builds on the success of the …